Microglia

Microglia are the resident immune cells of the central nervous system. Unlike other immune cells that circulate through the bloodstream, microglia take up permanent residence in the brain and spinal cord early in development, where they remain for life. Their name derives from their small size and glial origin—glia being the support cells once thought to merely hold neurons in place. But microglia are far from passive. They extend and retract delicate processes constantly, surveilling their microenvironment with a vigilance that rivals any border patrol. They prune synapses during development and learning, clear debris after injury, release signaling molecules that modulate neuronal excitability, and respond to pathogens, metabolic disturbances, and psychological stress. In doing so, they shape not only the structure of neural circuits but also their function—influencing mood, cognition, pain perception, and behavior. Microglia are neither purely protective nor purely destructive. They exist along a functional continuum, adopting states that range from surveillant and supportive to reactive and inflammatory, depending on context. This plasticity makes them essential partners in brain health and central actors in a wide range of neurological and psychiatric conditions.

For most of the twentieth century, the brain was understood as an immunologically privileged site—a fortress sealed off from the body's immune system by the blood-brain barrier. Microglia were acknowledged but largely ignored, treated as housekeepers rather than participants in cognition or emotion. That view has collapsed. We now know that microglia are active contributors to nearly every aspect of brain function, from the sculpting of synapses in childhood to the modulation of mood in adulthood to the progression of neurodegenerative disease in old age. This shift has profound implications. It means that inflammation is not something that happens to the brain from the outside, but something the brain does, through its own immune cells, in response to internal and external signals. It means that the line between neuroscience and immunology is not a line at all. It means that experiences we think of as purely psychological—chronic stress, social isolation, trauma—can alter the behavior of immune cells inside the brain, which in turn alter the way we think and feel. It also means that conditions long considered purely neurological or psychiatric may have immune dimensions that were previously invisible. Depression, chronic pain, cognitive decline after infection, even aspects of autism and schizophrenia—all show signatures of microglial involvement. Understanding microglia does not reduce these experiences to inflammation, but it does clarify why interventions that seem peripheral—sleep, movement, diet, social connection—can have such central effects. The immune system lives inside your brain. What you do with your body shapes what happens in your mind, at a cellular level.

Microglia originate from yolk sac progenitors that migrate into the developing brain before birth, a lineage distinct from other immune cells (Ginhoux et al., 2010). Once embedded in neural tissue, they proliferate locally and persist throughout life, with minimal replacement from circulating monocytes under normal conditions. During early development, microglia play a critical role in synaptic pruning, selectively eliminating weak or excess synapses through a process mediated by complement proteins and phagocytic engulfment (Schafer et al., 2012). This pruning is essential for normal circuit refinement, and its dysregulation has been implicated in neurodevelopmental disorders including autism spectrum conditions and schizophrenia (Presumey et al., 2017).

In the adult brain, microglia maintain a ramified, surveillant morphology, continuously extending and retracting fine processes to sample the extracellular environment. They respond rapidly to changes in neuronal activity, ATP release, and damage-associated molecular patterns. Upon activation, microglia undergo morphological transformation, retracting processes and adopting an amoeboid shape, while upregulating surface receptors and releasing cytokines, chemokines, and reactive oxygen species (Nimmerjahn et al., 2005). These responses exist along a spectrum rather than in discrete categories. The outdated M1/M2 classification has given way to recognition of context-dependent, heterogeneous microglial states shaped by local cues (Ransohoff, 2016).

Microglial activation is implicated in chronic pain states. In animal models of nerve injury, spinal microglia release pro-inflammatory cytokines such as interleukin-1 beta and tumor necrosis factor-alpha, which enhance neuronal excitability and contribute to central sensitization (Ji et al., 2013). Pharmacological inhibition of microglial activation can reduce pain behaviors in these models, though translation to human therapeutics has proven difficult.

In depression, postmortem studies and positron emission tomography imaging have revealed elevated microglial activation in cortical and limbic regions (Setiawan et al., 2015). Chronic stress in rodents induces microglial priming—a state of heightened reactivity—that correlates with depressive-like behaviors and can be reversed by anti-inflammatory interventions (Wohleb et al., 2016). The relationship is bidirectional: microglial cytokines influence neurotransmitter metabolism, particularly kynurenine pathway activity, which affects serotonin and glutamate signaling.

Microglia also play complex roles in neurodegenerative disease. In Alzheimer's disease, microglia cluster around amyloid plaques and may initially help clear pathological protein aggregates, but chronic activation appears to drive neuroinflammation and tau pathology (Heneka et al., 2015). Genetic variants in microglial genes, including TREM2 and CD33, are among the strongest risk factors for late-onset Alzheimer's disease, underscoring the centrality of immune function in neurodegeneration.

Emerging evidence links microglia to post-infectious cognitive symptoms. Following viral infections, including SARS-CoV-2, some individuals experience prolonged cognitive dysfunction, fatigue, and mood disturbance. Animal models suggest that systemic infection can prime microglia, leading to exaggerated inflammatory responses and altered synaptic function long after pathogen clearance (Dantzer et al., 2008). The mechanisms remain under investigation, but the phenomenon illustrates how peripheral immune events can have lasting central consequences mediated by resident brain immune cells.

Nervous System Intelligence treats the nervous system not as a command center issuing orders to a passive body, but as an embodied, distributed network engaged in constant dialogue with its environment—internal and external. Microglia are essential participants in that dialogue. They translate signals from the periphery—metabolic state, infection, injury, circadian rhythm—into changes in neural circuit function. They modulate synaptic strength, neuronal excitability, and neurotransmitter availability. They are, in effect, immune cells that think and nerve cells that inflame.

This dual identity challenges the conceptual boundaries we have inherited. NSI does not ask whether a symptom is neurological or immunological, psychological or physiological. It asks what the system is doing, and why. A microglial cell releasing cytokines in the prefrontal cortex is not malfunctioning when it alters mood in the context of chronic stress—it is responding to a perceived threat with tools shaped by evolution. The question is not whether the response is legitimate, but whether it remains adaptive in the context of modern life, where threats are often chronic, ambiguous, and unresolvable.

From an NSI perspective, microglial activity is not something to suppress or eliminate, but something to understand and, when necessary, modulate. Microglia are not the enemy. They are part of the system's attempt to maintain coherence under pressure. Interventions that support microglial health—adequate sleep, regular movement, management of chronic stressors—are not ancillary to mental health care. They are foundational. They work not by bypassing the brain's immune system, but by supporting it in returning to a surveillant, rather than reactive, state. This is not metaphor. It is mechanism.

Clinicians are increasingly confronted with patients whose symptoms do not fit neatly into diagnostic categories—chronic pain without clear structural pathology, depression resistant to monoaminergic antidepressants, cognitive fog following infection or trauma. Microglial biology offers a framework for understanding these presentations not as diagnostic failures but as expressions of neuroimmune dysregulation. This does not mean abandoning existing treatments, but it does mean expanding the clinical lens.

Assessment should include attention to factors known to influence microglial state: sleep quality and duration, history of infection or head injury, chronic stress exposure, metabolic health, and inflammatory markers when clinically indicated. While there are no widely available clinical biomarkers for microglial activation outside of research settings, the absence of a test does not negate the relevance of the biology. Clinical reasoning can incorporate what is known about microglial function even in the absence of direct measurement.

Pharmacological interventions targeting microglia remain largely experimental. Minocycline, a tetracycline antibiotic with anti-inflammatory properties, has shown modest effects in some trials for depression and schizophrenia, though results are inconsistent (Rosenblat & McIntyre, 2018). More selective microglial modulators are in development, but none have yet achieved regulatory approval for psychiatric or pain indications.

In the meantime, non-pharmacological interventions warrant greater clinical emphasis. Sleep deprivation activates microglia and increases inflammatory signaling; sleep restoration has the opposite effect. Physical activity modulates microglial phenotype in animal models, shifting cells toward anti-inflammatory states. Psychological interventions that reduce chronic stress—whether through cognitive therapy, mindfulness-based approaches, or social support—may exert part of their benefit through neuroimmune pathways.

Clinicians should also be cautious about overpromising. Microglial science is advancing rapidly, but it has not yet yielded transformative therapeutics. What it has done is validate a more integrated view of brain and body, one in which inflammation is neither villain nor bystander, but participant. That shift in perspective can itself be therapeutic, offering patients a more coherent narrative for their suffering and a broader set of tools for addressing it.

You cannot directly control your microglia, but you can influence the signals they receive. Sleep is among the most potent. During deep sleep, the brain's glymphatic system clears metabolic waste, and microglia shift toward restorative functions. Chronic sleep restriction does the opposite, priming microglia toward reactivity and increasing inflammatory tone. Prioritizing sleep is not self-care in the aspirational sense—it is immune care, enacted nightly.

Movement matters, though the mechanisms are still being mapped. Aerobic exercise in animal models reduces microglial activation in regions associated with mood and memory, and increases production of anti-inflammatory cytokines. The effect does not require intensity—regular, moderate activity appears sufficient. What matters is consistency, not performance.

Chronic stress is a reliable driver of microglial priming. This does not mean stress is avoidable or that you are failing if you experience it. It means that practices which help the nervous system return to baseline—whether through breathwork, time in nature, social connection, or creative engagement—are not luxuries. They are interventions with biological consequences that reach into the brain's immune architecture.

Diet may also play a role, though evidence in humans remains preliminary. Diets high in processed foods and refined sugars are associated with systemic inflammation, which can influence central immune function. Omega-3 fatty acids, found in fatty fish and certain plant sources, have anti-inflammatory properties and cross the blood-brain barrier. This is not about perfection or restriction—it is about recognizing that what you eat becomes part of the signaling environment your microglia inhabit.

Finally, context matters. Microglia respond not only to physical signals but to the meaning the nervous system assigns to experience. Chronic loneliness, perceived lack of control, and unresolved trauma all correlate with inflammatory markers. The inverse is also true. Connection, agency, and safety are not merely psychological constructs—they are immunological events. Care for the body is care for the mind, at a cellular level.